WMS-1 is under clinical development by WellMarker Bio and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WMS-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WMS-1 overview
WMS-1 is under development for the treatment of solid tumors including non-small cell lung cancer, colon cancer, bile duct cancer (cholangiocarcinoma), pancreatic cancer, colorectal cancer, head and neck cancer. It acts by targeting cetuximab-resistant gene (CRG). It is administered through oral route.
It was under development for the treatment of breast cancer.
WellMarker Bio overview
Wellmarker Bio discovers and develops anti-cancer drugs such as small molecules and biologics with predictive biomarkers for unmet medical needs. The company’s small molecule product pipeline includes WM-S1, WM-S2 and WM-S3. It also develops antibody candidates such as WM-A1 and VM-A2; and WM-P1. Wellmarker Bio products are used in the treating various therapeutics including liver cancer, head and neck cancer (H&N), solid tumors, non-small cell lung cancer (NSCLC), pancreatic and Cholangiocarcinoma, among others. It operates with a branch research institute in Gyeonggi-do, South Korea. Wellmarker Bio is headquartered in Seoul, South Korea.
For a complete picture of WMS-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
